Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in Inactive Non-infectious Intermediate, Posterior, or Pan-uveitis (Japan, Phase 3)
jRCT2080221173Phase 3
- Sponsor
- AbbVie Inc.
- Start
- Jun 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in uveitis comparing Adalimumab + Prednisone taper with Placebo + Prednisone taper (2 arms).
02
Drugs
03
Conditions
uveitis
Beyond the preview
Go deeper on jRCT2080221173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221173.